Sionna Therapeutics: A Breath of Fresh Air in Cystic Fibrosis Treatment
March 13, 2024, 1:37 pm
Location: United States, Massachusetts, Boston
Employees: 11-50
Founded date: 2019
Total raised: $293M
Sionna Therapeutics, a Boston-based life sciences company, recently secured a whopping $182 million in Series C funding to revolutionize cystic fibrosis (CF) treatment. Led by a team of experts, including CEO Mike Cloonan, Sionna is on a mission to restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, a key player in CF progression. With a focus on developing small molecules that target the root cause of CF, Sionna is paving the way for groundbreaking advancements in the field.
The Series C funding round, spearheaded by Enavate Sciences and joined by new investors like Viking Global Investors and Perceptive Advisors, marks a significant milestone for Sionna. Existing investors, including RA Capital and TPG’s The Rise Fund, also showed their continued support for the company's innovative approach to CF treatment. With this influx of capital, Sionna is well-positioned to accelerate its clinical development plan and achieve key milestones through 2026.
One of Sionna's key strategies is to stabilize the first nucleotide-binding domain (NBD1) of the CFTR protein, a crucial step in restoring its function. By targeting the most common CF-causing mutation, ΔF508, Sionna aims to correct the protein defects that underlie the disease. Through a combination of NBD1 stabilizers and complementary modulators, Sionna has demonstrated promising results in preclinical studies, showing the potential to restore CFTR function to wild-type levels.
In addition to its focus on NBD1, Sionna is advancing the development of compounds targeting other key mechanisms involved in CF. By targeting regions like the CFTR intracellular loop 4 (ICL4) and transmembrane domain 1 (TMD1), Sionna is taking a comprehensive approach to CF treatment. With ongoing clinical trials and plans to bring additional compounds to the forefront, Sionna is poised to make a significant impact on the lives of CF patients.
Mike Cloonan, Sionna's President and CEO, expressed his enthusiasm for the company's progress and the support from investors. He highlighted the importance of the Series C funding in enabling Sionna to execute its clinical development plan and deliver value-creating outcomes. With a strong team and a clear vision for the future, Sionna is well-equipped to lead the way in transforming CF treatment and improving the lives of patients worldwide.
The Series C funding round, spearheaded by Enavate Sciences and joined by new investors like Viking Global Investors and Perceptive Advisors, marks a significant milestone for Sionna. Existing investors, including RA Capital and TPG’s The Rise Fund, also showed their continued support for the company's innovative approach to CF treatment. With this influx of capital, Sionna is well-positioned to accelerate its clinical development plan and achieve key milestones through 2026.
One of Sionna's key strategies is to stabilize the first nucleotide-binding domain (NBD1) of the CFTR protein, a crucial step in restoring its function. By targeting the most common CF-causing mutation, ΔF508, Sionna aims to correct the protein defects that underlie the disease. Through a combination of NBD1 stabilizers and complementary modulators, Sionna has demonstrated promising results in preclinical studies, showing the potential to restore CFTR function to wild-type levels.
In addition to its focus on NBD1, Sionna is advancing the development of compounds targeting other key mechanisms involved in CF. By targeting regions like the CFTR intracellular loop 4 (ICL4) and transmembrane domain 1 (TMD1), Sionna is taking a comprehensive approach to CF treatment. With ongoing clinical trials and plans to bring additional compounds to the forefront, Sionna is poised to make a significant impact on the lives of CF patients.
Mike Cloonan, Sionna's President and CEO, expressed his enthusiasm for the company's progress and the support from investors. He highlighted the importance of the Series C funding in enabling Sionna to execute its clinical development plan and deliver value-creating outcomes. With a strong team and a clear vision for the future, Sionna is well-equipped to lead the way in transforming CF treatment and improving the lives of patients worldwide.